Acute Therapies
Strategic Growth Drivers
Portfolio Innovation Market Development
A
~$150M
400bps
2023 New Product Revenue¹
CRRT Penetration Increase
tuto
PrisMax
Baxter
Geographic
Expansion
Evidence
Generation
HCP
Education
Reimbursement Enablement
Enter Adjacencies +
2X
Organ Support Therapies (OST)
Revenue Over LRP
R&D Investment
Commercial Optimization
Innovation, Improving CRRT Penetration And Focus On OST Drive
Above-Market Growth Of 8% -9% Through 2023²
O
E17
¹All references to "new products" in this presentation include new product launches, line extensions and geographic expansions, unless otherwise noted. 2All references in this presentation to future financial
expectations assume commercial execution and regulatory approvals, as applicable, consistent with Baxter's plans. CAGRS for years 2018-2023 assume constant foreign exchange rates.
| 6View entire presentation